Vesicular monoamine transporter 2: role as a novel target for drug development - Test2 - elhamkhani - TriplyDB

Vesicular monoamine transporter 2: role as a novel target for drug development

Vesicular monoamine transporter 2: role as a novel target for drug development

http://www.wikidata.org/entity/Q24647764

about

Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans Tetrabenazine: Spotlight on Drug Review.The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats Experimenting with spirituality: analyzing The God Gene in a nonmajors laboratory course In Vitro and In Vivo Characterization of the Alkaloid Nuciferine Catecholamines up integrates dopamine synthesis and synaptic trafficking Reward processing in autism: a thematic series.Effect of high-fat feeding on expression of genes controlling availability of dopamine in mouse hypothalamus Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.Preparation and Characterization of Tetrabenazine Enantiomers against Vesicular Monoamine Transporter 2.New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2)Synthesis of H-Labeled Tetrabenazine (TBZ)The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.Brain dopamine and serotonin differ in regulation and its consequences Synthesis of (±)-Tetrabenazine by Visible Light Photoredox Catalysis Antiepileptic activity of lobeline isolated from the leaf of Lobelia nicotianaefolia and its effect on brain GABA level in mice Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters.Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease Sex differences in tolerance to the locomotor depressant effects of lobeline in periadolescent rats.N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.Dopamine D2 receptor relies upon PPM/PP2C protein phosphatases to dephosphorylate huntingtin protein Monoamine oxidases in development.The vesicular monoamine transporter 2: an underexplored pharmacological target.Synthesis of Lobeline, Lobelane and their Analogues. A Review.Stereocontrolled synthesis and pharmacological evaluation of cis-2,6-diphenethyl-1-azabicyclo[2.2.2]octanes as lobelane analogues.Therapeutic advances in the management of Huntington's disease.Novel hypoglycemic dihydropyridones serendipitously discovered from O- versus C-alkylation in the synthesis of VMAT2 antagonists.Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2.Using the affective bias test to predict drug-induced negative affect: implications for drug safety.Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse.Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats.A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2.Selection of sucrose concentration depends on the effort required to obtain it: studies using tetrabenazine, D1, D2, and D3 receptor antagonists.Altered expression of vesicular monoamine transporter 2 in epileptic patients and experimental rats.

P2860

Q24601233-98C71C81-BACF-4CCF-A554-E21E494AF284 Q24654140-FCC35ADE-55FC-45F2-9609-57DCF7D72121 Q27692599-63359918-E6F2-480D-86D0-7275692394B2 Q28267531-8F403D44-5960-4C19-9B02-D5BADE15FD0A Q28271336-BB78CD1A-95E0-44D5-88D7-9AEC816654C7 Q28550683-73A1A6DF-9D23-4D32-8AA7-6F50C3470E49 Q30423703-8B7ECAC3-1DFA-4277-9870-F21201D6578B Q30462673-9D50812E-AE5C-4037-92D8-3A75A26165BE Q33729782-1D419B48-DBAA-422A-AEE8-FD96E3DB70B9 Q33738102-F5815F44-1D6B-4B73-A0CC-B74F7EA03712 Q34042123-07E36BD0-1519-4B07-A97A-D5F63A94BB21 Q34823681-27FED988-5687-43D2-9804-532D7921F622 Q35076611-B7DF5714-52BE-4537-B6D8-B3F89B9A769B Q36079830-B9F7B36F-3745-43A2-8F64-2CD7A079AEAB Q36122702-415DD79A-7535-4446-86D6-5CA574AA8565 Q36386171-FE659F38-CAFD-4E8E-87A4-E6C955CC33D2 Q36719819-02AB861E-5B51-437A-B156-A6269B1D12B7 Q37052442-BAA7957F-E9AA-4322-8F9F-3787DC7FE1BE Q37052450-F3246F15-22A3-40A0-9852-4CF7BDC8A084 Q37081344-80F3525F-8C07-47C8-9954-892D092533EF Q37190441-A406F809-6076-4992-942A-5E094994E522 Q37227997-C5AFBAD0-8A44-43BF-9182-21DD48C9F723 Q37267145-5644E848-1A86-4C29-A371-94E411FEFAB7 Q37396979-07C4E1AC-BED3-4593-9193-96170B7C0E5A Q37589110-E909AC49-B0D7-4A64-82C2-2268D0C28798 Q37727587-A9105E46-C792-4B86-873A-99F1981E2C26 Q38025300-A376D432-D253-4580-85ED-A026E0C950EF Q38176494-90335DA4-CA55-4A7D-B544-BBC838F309B7 Q38267226-F640AE79-8869-4F43-B42D-A3B0FEFBE088 Q38274875-875F9F9B-D90D-46F2-B452-C0FFF2C1A6D2 Q38548033-2D18B907-99EA-4672-BD7D-1D1FE0D3A717 Q39992795-74CADCF8-DDCC-423B-BFA0-3DA2C5D41F1F Q40664282-38553BEB-F078-4596-8890-6E6279FC44B6 Q41203122-2FF89091-057A-4FE3-ABC1-3BC62DA1A183 Q42098885-0FC3E6FA-D66B-4B49-85FC-F632C2292C57 Q42864716-E652575A-C484-43FA-A24D-D3FDAA0013D8 Q45288855-8D451920-733C-4EF0-9980-3795FFC526D8 Q47387524-20A155D5-3CF6-4594-89AF-AB73239E632D Q47680336-DDE3A958-B014-49C5-B6A5-CD157AB59F42 Q48121473-75CE409C-45B4-42CC-A1D2-FAACE115F8BC

P2860

Vesicular monoamine transporter 2: role as a novel target for drug development

http://www.wikidata.org/entity/Q24647764

description

2006 nî lūn-bûn

@nan

2006 թուականին հրատարակուած գիտական յօդուած

@hyw

2006 թվականին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Vesicular monoamine transporter 2: role as a novel target for drug development

@ast

Vesicular monoamine transporter 2: role as a novel target for drug development

@en

Vesicular monoamine transporter 2: role as a novel target for drug development

@nl

type

label

Vesicular monoamine transporter 2: role as a novel target for drug development

@ast

Vesicular monoamine transporter 2: role as a novel target for drug development

@en

Vesicular monoamine transporter 2: role as a novel target for drug development

@nl

prefLabel

Vesicular monoamine transporter 2: role as a novel target for drug development

@ast

Vesicular monoamine transporter 2: role as a novel target for drug development

@en

Vesicular monoamine transporter 2: role as a novel target for drug development

@nl

P1433

Q24647764-18CC323C-BA5B-4DDD-BEFE-23DFC60C2125

P1476

Q24647764-ED890B4F-AEE4-4B57-B7F5-B2B8BD1D9094

P2093

Q24647764-8E1D9A0A-AB1E-45B8-98D0-05576D55B7F5

Q24647764-961D772B-87F9-4AE4-B532-36DC8C1D6C8D

Q24647764-D642E62C-6D24-40FC-9227-6C1CB7D8A29D

P2860

Q24647764-0172FE30-3B09-4A69-B236-C87810AFF652

Q24647764-0C2202C8-2054-4D47-B5B4-CE14D3CE373B

Q24647764-0C5198C6-A5B8-4BBD-8D19-E0FE7ED0220B

Q24647764-0D144015-0A5B-4C89-85EC-9D7C4189F5F3

Q24647764-0D751B37-F637-4BE4-A0A5-F1CC62B3CA63

Q24647764-0F7D3C66-7368-4FFC-9930-CE5F07FCD022

Q24647764-120629DA-40AC-4E51-8016-432ED482CC4A

Q24647764-14104A23-D5B7-4B2D-80FC-CF155BB40CFB

Q24647764-1423BE9F-EC99-4576-83D9-3D38067E99C6

Q24647764-144A19E8-4D8E-4134-A53F-67A9C8A4485A

P2888

Q24647764-353B2C39-0935-45A3-BBF8-73810E250E84

P304

Q24647764-CA1FE38B-6686-4198-93F5-ED01D9E66F85

P31

Q24647764-8CDBD84A-D061-4F31-B533-FB5300397EB0

P356

Q24647764-4FC784DD-9C1D-4652-8F71-E02999E5AA27

P407

Q24647764-48A09AA0-C9E8-49A1-9E37-6C947365AF6A

P433

Q24647764-0B28CF83-FFA8-4173-B3BD-4277F5698F52

P478

Q24647764-E885FF38-0F6B-404A-889A-1244E7D93467

P577

Q24647764-0464B418-0099-40D7-9074-3A6A5205C03D

P5875

Q24647764-46F7B8CB-A6B3-42B8-A92B-6EE2378EF007

P6179

Q24647764-B0E2460D-27BB-4D27-B6DF-98496F4CEDDC

P698

Q24647764-216BEBC7-EEE0-4FB5-8C37-FC6B0B5AC790

P932

Q24647764-2C564084-ABFD-4EE0-B840-13D81FFB22EA

P356

P1433

The AAPS Journal

P1476

Vesicular monoamine transporter 2: role as a novel target for drug development

@en

P2093

Guangrong Zheng

http://www.w3.org/2001/XMLSchema#string

Linda P Dwoskin

http://www.w3.org/2001/XMLSchema#string

Peter A Crooks

http://www.w3.org/2001/XMLSchema#string

P2860

Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter

Expression cloning of a reserpine-sensitive vesicular monoamine transporter

Role of monoamine transporters in mediating psychostimulant effects

Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants

Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats

Pharmacology of lobeline, a nicotinic receptor ligand

Functional identification and molecular cloning of a human brain vesicle monoamine transporter

Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter

Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport

A benzo[a]quinolizine derivative with a neuroleptic-like action on cerebral monoamine turnover

P2888

P304

E682-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/AAPSJ080478

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6568320

http://www.w3.org/2001/XMLSchema#string

P6179

1045528640

http://www.w3.org/2001/XMLSchema#string

P698

17233532

http://www.w3.org/2001/XMLSchema#string

P932

2751365

http://www.w3.org/2001/XMLSchema#string